Deucrictibant

Rx-PHVS-2704PHVS/FDA decisionResearch

Pharvaris · on-demand treatment of hereditary angioedema attacksApr 23, 2027 target

Will the FDA approve Deucrictibant for on-demand treatment of hereditary angioedema attacks?

Drug profile Company Event Small moleculeNCT06343779

Primary source

YPHVS

PHVS-YES/ USDC

Outcome claim / Research candidate

NOT LISTED

Executable price

—

Change across observed prices in this window

Implied YES probability—Price-based, not a clinical forecast

Market not listed

No market price yet.

This program has no funded pool or observed trading history. Start with the evidence, or explore a clearly labeled scenario.

0 trading observationsNo live price feed

YES —NO —

This chart stays empty until observations exist. Research status is not an approval probability. A sandbox session creates a separate virtual price history.

Rx-PHVS-2704 / Evidence

Unlisted

Pool price—No deployed pool

Dated model P(YES)—No dated model artifact

Days to sponsor target172Date-only guidance

Source publishedJul 6, 2026

Research snapshotOct 28, 2026

FDA targetApr 23, 2027

Small moleculeNCT06343779

A pool price describes trading inventory; a model estimates an outcome. Neither a live price nor a dated forecast is available for this unlisted catalyst.

Program overview

Sponsor describes an oral small-molecule B2 antagonist, RAPIDe-3 and an April 23, 2027 FDA target.

THERAPEUTIC AREAImmunology

DRUG / PROGRAMDeucrictibant

INDICATIONon-demand treatment of hereditary angioedema attacks

REGULATORY TARGETApril 23, 2027

Agent model / unavailable

No reviewed probability or reasoning artifact is available. A neutral pool opening is not a clinical base rate.

What matters

HAE economic theme overlaps NTLA; avoid correlated concentration and do not confuse IR with XR prophylaxis.
Approval, the stock price and commercial success are different outcomes. A claim only pays on its specified event.
Future program funding and tokenized financing require separate rights and contracts. An event claim gives no equity, royalty or drug IP.

Try virtual trading